NASDAQ · Biotechnology

BTAI (BTAI) Stock

$0.07 +0.00% NASDAQ: BTAI Healthcare

Valuation

MetricValue
Price$0.07
Market Cap$2.28M
P/E Ratio-0.02
P/B Ratio-0.01
P/S Ratio4.45
EPS (TTM)$0.00
52-Week High$4.29
52-Week Low$0.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE69.92%
ROA-246.05%
ROCE41.19%
Gross Margin-5000.00%
Operating Margin-5000.00%
Net Margin-110.79%
Debt/Equity-0.90
Current Ratio0.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$2.0M$1.0M
Operating Profit$-107.0M$-160.0M$-172.0M$-67.0M$-50.0M
Net Profit$-107.0M$-166.0M$-179.0M$-60.0M$-70.0M
EPS$-64.87$-94.67$-98.35$-23.51$-5.73
Op Margin—-42572.0%-12448.0%-2967.6%-7829.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$239.0M$206.0M$74.0M$38.0M$45.0M
Total Liabilities$18.0M$129.0M$130.0M$131.0M$140.0M
Cash$233.0M$194.0M$65.0M$30.0M$28.0M
Borrowings$1.0M$94.0M$101.0M$103.0M$110.0M

Latest News

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock Zacks · Jun 2, 2026 BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting GlobeNewswire · May 28, 2026 BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 15, 2026 BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026 CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates Zacks · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$-135.0M$-155.0M$-72.0M$-58.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$1.0M$-3.0M$-1.0M$-1.0M$0
Net Cash Flow$20.0M$-39.0M$-129.0M$-35.0M$-1.0M
Free Cash Flow$-83.0M$-135.0M$-155.0M$-72.0M$-58.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.78
FCF Yield-1540.72%
Quick Ratio0.21
Interest Coverage-2.59
Return 1Y-51.05%
Return 3Y-99.44%
Return 5Y-99.79%

Ownership

Insiders Held3.65%
Institutions Held18.72%
Institutions Float Held19.43%
Institutional HolderSharesReport Date
Millennium Management Llc1,936,7602026-03-31
Armistice Capital, LLC1,910,0762026-03-31
Oaktree Capital Management LP241,1882026-03-31
Geode Capital Management, LLC230,1682026-03-31
Vanguard Capital Management LLC207,3392026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVSAnnovis Bio, Inc. $1.00 +0.77% -0.56 $42.65M 0.00%
BCAB $1.74 +0.00% -0.12 $2.88M 0.00%
CELUCelularity Inc. $0.98 -6.89% -0.46 $31.73M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About BTAI

BTAI is led by CEO Vimal D. Mehta, employs 37 people, headquartered in US, publicly traded since 2018.

BTAI stock trades at $0.07 with a market capitalization of $2.28M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.02, reflecting a net loss over the last twelve months, a negative price-to-book of -0.01, reflecting negative shareholders' equity, price-to-sales of 4.45. Over the past 52 weeks the stock has ranged between $0.07 and $4.29, and currently trades 98.4% below its 52-week high.

On profitability, BTAI generates a return on equity (ROE) of 69.92% (not meaningful, as shareholders' equity is negative), return on capital employed of 41.19%, an operating margin of -5000.00%, a net profit margin of -110.79%.

BTAI by the numbers, 2016–2025

Between 2016 and 2025 BTAI reported revenue of $0 rising to $1.0M. Compounded, revenue has grown —% a year over five years, —% over three, -50.0% over the last twelve months. Net profit fell to $-70.0M.

The most recent net margin is -110.79%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-72.0M.

Borrowings stand at $110.0M, cash from operations was $-58.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged 37.7% over five years, and was 73.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BTAI (BTAI) — frequently asked questions

What is BTAI (BTAI) stock price today?

BTAI (BTAI) is currently trading at $0.07, up 0% today.

What is BTAI P/E ratio?

BTAI's P/E ratio is -0.02. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is BTAI return on equity (ROE)?

BTAI's return on equity (ROE) is 69.92%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is BTAI's market cap?

BTAI has a market capitalization of $2.28M.

Does BTAI pay a dividend?

BTAI is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does BTAI carry?

BTAI has a debt-to-equity ratio of -0.90. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is BTAI's profit margin?

BTAI reports a net profit margin of -110.79% — the share of revenue left after every cost, including tax and interest.

What sector is BTAI in?

BTAI is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is BTAI listed on?

BTAI trades on NASDAQ under the ticker BTAI.

What is BTAI's 52-week range?

Over the last year BTAI has traded between $0.07 and $4.29.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens BTAI currently matches

On the figures above, BTAI passes the filters for 2 of our ready-made screens, among them Stocks Under $1, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Stocks Under $1Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.